Phenytoin metabolic ratio: A putative marker of CYP2C9 activity in vivo

Pharmacogenetics

Volumn 11, Issue 7, 2001, Pages 587-596

  Caraco, Y ^a   Muszkat, M ^a   Wood, A J J ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

CYP2C9; Genotyping; Phenotyping; Phenytoin

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; BIOLOGICAL MARKER; CYTOCHROME P450 2C9; PHENYTOIN;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENANTIOMER; ENZYME ACTIVITY; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; ISOENZYMES; MALE; METABOLIC CLEARANCE RATE; PHENYTOIN;

EID: 0034785607     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200110000-00005     Document Type: Article

References (44)

1. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
2. Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations
3. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
4. Michaelis-Menten kinetics and the steady state serum phenytoin/hydroxyphenytoin ratio
5. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes
6. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin
7. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fiuvastatin: Effect on human cytochrome P-450 and implication for metabolic drug interactions
8. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans
9. Phenytoin metabolism in subjects with long and short plasma half-life
10. In vivo techniques for studying drug metabolism
11. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C
12. Phenytoin hydroxylation in a healthy Caucasian population: Bimodal distribution of hydroxyphenytoin urinary excretion
13. Stereoselective 4′-hydroxylation of phenytoin: Relationship to (S)-mephenytoin polymorphism in Japanese
14. Phenytoin: Pharmacogenetic polymorphism of 4′-hydroxylation
15. Human P450 metabolism of warfarin
16. Pharmacokinetics of chlorpheniramin3, phenytoin, glipizide and nifedipine in an individual homozygous for CYP2C9*3 allele
17. Use of probe drugs as predictors of drug metabolism in humans
18. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity
19. The effect of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
20. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174
21. The effect of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
22. Overview of enzymes of drug metabolism
23. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
24. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
25. A screening test for slow metabolizers of tolbutamide
26. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
27. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
28. Liquid chromatographic method for simultaneous determination of phenytoin and 5-(4-hydroxy-phenyl)-5-phenylhydantoin in plasma and urine
29. Pharmacogenetics of tolbutamide metabolism in humans
30. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
31. Genetic association between sensitivity to warfarin and expression of CYP2C9*3
32. Phenotypicgenotypic analysis of CYP2C19 in the Jewish Israeli population
33. Metabolism of warfarin enantiomers in Japanese with heart disease having different CYP2C9 and CYP2C19 genotypes
34. 359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes
35. Co-regulation of phenytoin and tolbutamide metabolism in humans
36. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo
37. Use of midazolam as a human cytochrome P450 3A probe: In vitro - In vivo correlations in liver transplant patients
38. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes
39. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family
40. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers
41. Tolbutamide hydroxylation in human: Lack of bimodality in 106 healthy subjects
42. Noninvasive tests of CYP3A enzymes
43. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
44. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: Difference in chiral preference of CYP2C9 and CYP2C19